@article{fa3b775e6ce44793902de47da480f484,
title = "Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers",
author = "Kunle Odunsi and Tanja Pejovic",
note = "Funding Information: reported receiving grants from the National Cancer Institute during the conduct of the study; grants from AstraZeneca and TESARO, Inc, personal fees from Merck & Co, Genentech, Immunovaccine, Inc, and Unleash Immuno Oncolytics, nonfinancial support from Truvax, Inc, and other from Tactiva Therapeutics outside the submitted work; issue and license of patent PCT/US2014025673; being a cofounder of Tactiva Therapeutics; and serving as an advisor to Immunovaccine, Inc, Unleash Immuno Oncolytics, Truvax, and Merck & Co. Dr Pejovic reported receiving personal fees from TESARO, Inc, outside the submitted work and serving as a consultant to TESARO, Inc. No other disclosures were reported.",
year = "2019",
month = aug,
doi = "10.1001/jamaoncol.2019.1009",
language = "English (US)",
volume = "5",
pages = "1103--1105",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "8",
}